ArticleScientific reports2025
Spatial heterogeneity and temporal trends of thyroid cancer incidence in Iran from 2014 to 2017.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spatiotemporal Epidemiology of Female Thyroid Cancer: A Retrospective Population-Based Registry Study in the Hamadan Province, Iran (2010-2019).Archives of Iranian medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Global thyroid cancer (TC) incidence has risen sharply, yet subnational spatial and temporal patterns, particularly in middle-income contexts like Iran, remain understudied. This study investigates TC's spatial heterogeneity and temporal trends across Iran (2014-2017) to delineate high-risk clusters and guide targeted interventions. Data from the Iranian National Cancer Registry (18,336 cases) were analyzed, with age-standardized rates (ASRs) computed via direct standardization and annual percent changes (APCs) estimated using Poisson regression. Global and Local Moran's I statistics evaluated spatial autocorrelation and clustering by sex, and province. The four-year ASR in Iran was 11.1 per 100,000 (95% CI: 0-28.2), with females at 35.1 (95% CI: 27.4-42.7) versus males at 9.64 (95% CI: 5.9-13.4), reflecting a 3.6-fold sex disparity. Annual ASRs increased from 2.1 to 3.6 per 100,000 (APC: 19.6%), with females (17.6%) exceeding males (11.2%). Grade 9 tumors prevailed (88.2%), most prevalent in females (69.9%) and Yazd (14.5%), rising from 16.8% in 2014 to 28.1% in 2017. Spatial analysis identified high-high clusters in central provinces (e.g., Yazd: 36.6, Esfahan: 17.5 per 100,000) versus low-low clusters in the northeast (e.g., Semnan: 4.8). Peak incidence occurred at 50-54 years (females) and 70-74 years (males). Thyroid Cancer in Iran displays marked sex, geographic, and temporal disparities, propelled by diagnostic enhancements and environmental influences. Standardized registries and selective screening in high-risk zones (e.g., Yazd, Esfahan) are imperative to address this growing burden, aligning with precision public health strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.